T1	CHEM 57 69	ceralasertib
T2	CHEM 74 84	durvalumab
#1	AnnotatorNotes T2	C4055109; durvalumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T3	CHEM 94 103	docetaxel
#2	AnnotatorNotes T3	C0246415; docetaxel; Organic Chemical · Pharmacologic Substance
T4	LIVB 107 116	pacientes
#3	AnnotatorNotes T4	C0030705; Patients; Patient or Disabled Group
T5	DISO 121 152	cáncer de pulmón no microcítico
#4	AnnotatorNotes T5	C0007131; Non-Small Cell Lung Carcinoma; Neoplastic Process
T6	Neg_cue 138 140	no
T7	Negated 141 152	microcítico
T8	DISO 164 175	metastásico
#5	AnnotatorNotes T8	C4255448; Metastasis; Pathologic Function
T9	PROC 198 256	Estudio de fase III, abierto, aleatorizado y multicéntrico
T10	CHEM 261 273	ceralasertib
T11	CHEM 278 288	durvalumab
#6	AnnotatorNotes T11	C4055109; durvalumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T12	CHEM 298 307	docetaxel
#7	AnnotatorNotes T12	C0246415; docetaxel; Organic Chemical · Pharmacologic Substance
T13	LIVB 311 320	pacientes
#8	AnnotatorNotes T13	C0030705; Patients; Patient or Disabled Group
T14	DISO 325 356	cáncer de pulmón no microcítico
#9	AnnotatorNotes T14	C0007131; Non-Small Cell Lung Carcinoma; Neoplastic Process
T15	Neg_cue 342 344	no
T16	Negated 345 356	microcítico
T17	DISO 368 379	metastásico
#10	AnnotatorNotes T17	C4255448; Metastasis; Pathologic Function
T18	Neg_cue 380 383	sin
T19	DISO 384 406	alteraciones genómicas
T20	Negated 384 406	alteraciones genómicas
T21	DISO 445 455	enfermedad
#11	AnnotatorNotes T21	C0012634; Disease; Disease or Syndrome | C0221423; Illness (finding); Sign or Symptom
T22	PROC 494 505	tratamiento
#12	AnnotatorNotes T22	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T23	CHEM 517 529	anti-PD-(L)1
T24	PROC 532 545	quimioterapia
#13	AnnotatorNotes T24	C0013216; Pharmacotherapy; Therapeutic or Preventive Procedure | C0392920; Chemotherapy Regimen; Therapeutic or Preventive Procedure | C3665472; Chemotherapy; Therapeutic or Preventive Procedure
T25	CHEM 559 566	platino
#14	AnnotatorNotes T25	C0032207; platinum; Element, Ion, or Isotope
T26	DISO 598 614	Cáncer de pulmón
#15	AnnotatorNotes T26	C0242379; Malignant neoplasm of lung; Neoplastic Process | C0684249; Carcinoma of lung; Neoplastic Process
T27	DISO 641 672	Cáncer de pulmón no microcítico
#16	AnnotatorNotes T27	C0007131; Non-Small Cell Lung Carcinoma; Neoplastic Process
T28	Neg_cue 658 660	no
T29	Negated 661 672	microcítico
T30	DISO 684 695	metastásico
#17	AnnotatorNotes T30	C4255448; Metastasis; Pathologic Function
T31	LIVB 725 737	Participante
T32	Age 747 758	>/= 18 años
T33	DISO 794 825	Cáncer de pulmón no microcítico
#18	AnnotatorNotes T33	C0007131; Non-Small Cell Lung Carcinoma; Neoplastic Process
T34	Neg_cue 811 813	no
T35	Negated 814 825	microcítico
T36	DISO 827 853	non-small cell lung cancer
T37	DISO 855 860	NSCLC
#19	AnnotatorNotes T37	C0007131; Non-Small Cell Lung Carcinoma; Neoplastic Process
T38	PROC 875 904	histológica o citológicamente
T39	DISO 928 939	metastásico
#20	AnnotatorNotes T39	C4255448; Metastasis; Pathologic Function
T40	DISO 1124 1151	Progresión de la enfermedad
#21	AnnotatorNotes T40	C0242656; Disease Progression; Pathologic Function
T41	DISO 1177 1179	PD
T42	PROC 1292 1330	tratamiento de segunda o tercera línea
T43	PROC 1348 1372	tratamiento anti-PD-(L)1
T44	PROC 1375 1390	biquimioterapia
T45	CHEM 1395 1416	derivados del platino
T46	DISO 1422 1427	NSCLC
#22	AnnotatorNotes T46	C0007131; Non-Small Cell Lung Carcinoma; Neoplastic Process
T47	DISO 1450 1461	metastásico
#23	AnnotatorNotes T47	C4255448; Metastasis; Pathologic Function
T48	Duration 1630 1640	12 semanas
T49	PROC 1646 1659	Peso corporal
T50	Neg_cue 1670 1673	sin
T51	DISO 1674 1693	caquexia neoplásica
T52	Negated 1674 1693	caquexia neoplásica
T53	PROC 1699 1717	Prueba de embarazo
#24	AnnotatorNotes T53	C0032976; Pregnancy Tests; Diagnostic Procedure
T54	Negated 1709 1717	embarazo
T55	Neg_cue 1718 1726	negativa
T56	ANAT 1731 1736	suero
#25	AnnotatorNotes T56	C0229671; Serum; Body Substance | C0588987; Serum product; Body Substance
T57	LIVB 1745 1776	mujeres potencialmente fértiles
T58	Spec_cue 1753 1767	potencialmente
T59	Speculated 1768 1776	fértiles
T60	LIVB 1807 1819	Participante
T61	PROC 1824 1840	histología mixta
T62	DISO 1844 1891	carcinoma pulmonar microcítico y no microcítico
T63	Neg_cue 1877 1879	no
T64	Negated 1880 1891	microcítico
T65	DISO 1917 1943	neoplasia maligna primaria
#26	AnnotatorNotes T65	C1306459; Primary malignant neoplasm; Neoplastic Process
T66	Neg_cue 1945 1952	excepto
T67	PROC 1967 1974	tratada
T68	Negated 1967 1974	tratada
T69	Neg_cue 2000 2002	no
T70	Negated 2017 2043	actividad de la enfermedad
T71	DISO 2033 2043	enfermedad
#27	AnnotatorNotes T71	C0012634; Disease; Disease or Syndrome | C0221423; Illness (finding); Sign or Symptom
T72	Duration 2044 2054	>/= 5 años
T73	PROC 2085 2096	tratamiento
#28	AnnotatorNotes T73	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T74	DISO 2113 2128	Efectos tóxicos
#29	AnnotatorNotes T74	C0600688; Toxic effect; Injury or Poisoning
T75	PROC 2174 2200	tratamiento antineoplásico
T76	DISO 2212 2255	Trastornos autoinmunitarios o inflamatorios
T77	LIVB 2291 2304	Participantes
T78	CHEM 2344 2356	anti-PD-(L)1
T79	LIVB 2402 2415	participantes
T80	Neg_cue 2421 2423	No
T81	DISO 2447 2456	toxicidad
#30	AnnotatorNotes T81	C0600688; Toxic effect; Injury or Poisoning
T82	Negated 2447 2456	toxicidad
T83	PROC 2476 2525	suspensión permanente del tratamiento anti-PD(L)1
T84	DISO 2585 2609	acontecimientos adversos
#31	AnnotatorNotes T84	C0877248; Adverse event; Pathologic Function
T85	DISO 2627 2629	AE
T86	PROC 2652 2675	tratamiento anti-PD(L)1
T87	Neg_cue 2689 2691	No
T88	Negated 2715 2739	AE de origen inmunitario
T89	Negated 2741 2771	immune-mediated adverse events
T90	Neg_cue 2794 2796	ni
T91	DISO 2797 2843	AE neurológicos u oculares de tipo inmunitario
T92	Negated 2797 2843	AE neurológicos u oculares de tipo inmunitario
T93	Neg_cue 2847 2853	ningún
T94	Negated 2854 2859	grado
T95	PROC 2871 2894	tratamiento anti-PD(L)1
T96	Neg_cue 2907 2909	No
T97	PROC 2932 2947	inmunosupresión
#32	AnnotatorNotes T97	C0021079; Therapeutic immunosuppression; Therapeutic or Preventive Procedure
T98	Negated 2932 2947	inmunosupresión
T99	CHEM 2970 2986	corticosteroides
#33	AnnotatorNotes T99	C0001617; Adrenal Cortex Hormones; Hormone · Organic Chemical · Pharmacologic Substance
T100	Negated 2970 2986	corticosteroides
T101	PROC 2995 3006	tratamiento
#34	AnnotatorNotes T101	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T102	DISO 3013 3015	AE
T103	Neg_cue 3017 3019	no
T104	Negated 3043 3063	reaparición de un AE
T105	DISO 3043 3054	reaparición
T106	DISO 3061 3063	AE
T107	Neg_cue 3090 3092	no
T108	Date 3108 3124	en la actualidad
T109	Negated 3125 3169	dosis de mantenimiento > 10 mg de prednisona
T110	CHEM 3159 3169	prednisona
#35	AnnotatorNotes T110	C0032952; prednisone; Hormone · Organic Chemical · Pharmacologic Substance
T111	Frequency 3184 3190	al día
T112	LIVB 3195 3208	Participantes
T113	PROC 3255 3268	quimioterapia
#36	AnnotatorNotes T113	C0013216; Pharmacotherapy; Therapeutic or Preventive Procedure | C0392920; Chemotherapy Regimen; Therapeutic or Preventive Procedure | C3665472; Chemotherapy; Therapeutic or Preventive Procedure
T114	CHEM 3273 3294	derivados del platino
T115	DISO 3300 3322	enfermedad metastásica
#37	AnnotatorNotes T115	C0341683; Hydatid cyst of kidney; Disease or Syndrome
T116	LIVB 3327 3340	Participantes
T117	CHEM 3363 3379	inhibidor de ATR
T118	PROC 1033 1037	EGFR
T119	PROC 1040 1043	ALK
T120	PROC 1181 1192	radiológica
T121	DISO 2611 2625	adverse events
T122	Dose 3125 3155	dosis de mantenimiento > 10 mg
T123	DISO 2715 2739	AE de origen inmunitario
#38	AnnotatorNotes T123	Immune-mediated adverse reaction A26715052 ( pathologic function)
T124	DISO 2741 2771	immune-mediated adverse events
T125	DISO 2773 2777	imAE
T126	Negated 2773 2777	imAE
T127	PROC 1248 1259	tratamiento
T128	PROC 1083 1112	determinación del laboratorio
#39	AnnotatorNotes T128	Laboratory reporting C0200370
T129	DISO 1153 1175	progression of disease
T130	PROC 1505 1521	Estado funcional
T131	PHYS 2552 2571	resolución completa
#40	AnnotatorNotes T131	total recovery C0683340
T132	PROC 1548 1570	Funcionalidad orgánica
T133	PROC 1573 1588	reserva medular
T134	Quantifier_or_Qualifier 153 161	avanzado
T135	Quantifier_or_Qualifier 357 365	avanzado
T136	Quantifier_or_Qualifier 407 437	aprovechables terapéuticamente
T137	Observation 461 471	progresado
T138	Quantifier_or_Qualifier 673 681	avanzado
T139	Quantifier_or_Qualifier 906 925	localmente avanzado
T140	Quantifier_or_Qualifier 1044 1059	de tipo natural
T141	Quantifier_or_Qualifier 1428 1447	localmente avanzado
T142	CONC 1526 1534	ECOG/WHO
T143	Result_or_Value 1538 1543	0 o 1
T144	Observation 1548 1572	Funcionalidad orgánica y
T145	Observation 1573 1598	reserva medular adecuadas
T146	CONC 1602 1619	Esperanza de vida
T147	Result_or_Value 1660 1667	> 30 kg
T148	Result_or_Value 1718 1726	negativa
T149	Quantifier_or_Qualifier 1768 1776	fértiles
T150	Quantifier_or_Qualifier 1975 1997	con intención curativa
T151	CONC 2067 2080	primera dosis
T152	Quantifier_or_Qualifier 2133 2142	grado > 2
T153	CONC 2150 2155	CTCAE
T154	Quantifier_or_Qualifier 2157 2169	persistentes
T155	Quantifier_or_Qualifier 2256 2263	activos
T156	Quantifier_or_Qualifier 2324 2340	más de una línea
T157	Quantifier_or_Qualifier 2372 2376	sola
T158	Observation 2552 2571	resolución completa
T159	Quantifier_or_Qualifier 2718 2739	de origen inmunitario
T160	Quantifier_or_Qualifier 2782 2793	grado >/= 3
T161	CONC 3125 3130	dosis
T162	Quantifier_or_Qualifier 3134 3147	mantenimiento
T163	Quantifier_or_Qualifier 3228 3244	más de una línea
T164	Patient 107 116	pacientes
T165	Patient 311 320	pacientes
T166	History_of 494 505	tratamiento
T167	History_of 517 529	anti-PD-(L)1
T168	History_of 532 545	quimioterapia
T169	History_of 559 566	platino
T170	Patient 725 737	Participante
T171	History_of 1237 1259	régimen de tratamiento
T172	History_of 1375 1390	biquimioterapia
T173	History_of 1409 1416	platino
T174	Patient 1745 1776	mujeres potencialmente fértiles
T175	Patient 1807 1819	Participante
T176	History_of 1917 1934	neoplasia maligna
T177	History_of 1935 1943	primaria
T178	History_of 1967 1974	tratada
T179	History_of 2174 2200	tratamiento antineoplásico
T180	History_of 2212 2255	Trastornos autoinmunitarios o inflamatorios
T181	Patient 2291 2304	Participantes
T182	History_of 2344 2356	anti-PD-(L)1
T183	Patient 2402 2415	participantes
T184	History_of 2447 2456	toxicidad
T185	History_of 2502 2525	tratamiento anti-PD(L)1
T186	History_of 2652 2663	tratamiento
T187	History_of 2664 2675	anti-PD(L)1
T188	History_of 2715 2717	AE
T189	History_of 2741 2747	immune
T190	History_of 2757 2764	adverse
T191	History_of 2765 2771	events
T192	History_of 2797 2823	AE neurológicos u oculares
T193	History_of 2871 2894	tratamiento anti-PD(L)1
T194	History_of 2932 2947	inmunosupresión
T195	History_of 2970 2986	corticosteroides
T196	Patient 3195 3208	Participantes
T197	History_of 3255 3268	quimioterapia
T198	History_of 3287 3294	platino
T199	Patient 3327 3340	Participantes
T200	History_of 3363 3379	inhibidor de ATR
